GGrantIndex
← Leaderboards

Medical Technology And Practice Patterns

Bethesda, MD

Compare ↔
$3,891,187
Total funding
11
Grants

Funding over time

peak $701.6K · FY200517
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17

Funding mix

By agency

AHRQ$2,600,045 · 7
NIH$1,286,142 · 3
FDA$5,000 · 1

By mechanism

R01$2,506,177 · 3
R21$992,611 · 3
R03$387,399 · 4
R13$5,000 · 1

Investigators at Medical Technology And Practice Patterns

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

Not enough data

Largest grants

ESA Outcomes among Anemic CKD Patients$489,991
R01 · FY2012 · HS
ESA Outcomes among Anemic CKD Patients$466,338
R01 · FY2013 · HS
Individualized Treatment Strategies and Optimal Hematocrit Target for Complex Dia$422,455
R21 · FY2010 · HS
Epoetin Therapy and Survival of Hemodialysis Patients$364,680
R01 · FY2005 · DK
Epoetin Therapy and Survival of Hemodialysis Patients$351,306
R01 · FY2006 · DK
ESA Outcomes among Anemic CKD Patients$326,764
R01 · FY2014 · HS
IMPACT OF THE ESRD PPS REFORM ON EFFICIENCY OF DIALYSIS PROVIDERS AND THE IMPACT ON QUALITY OF CARE AND PATIENTOUTCOMES$253,549
R01 · FY2017 · HS
IMPACT OF THE ESRD PPS REFORM ON EFFICIENCY OF DIALYSIS PROVIDERS AND THE IMPACT ON QUALITY OF CARE AND PATIENTOUTCOMES$253,549
R01 · FY2016 · HS
Creation of a Risk-scoring Algorithm for Early Mortality Among Elderly ESRD Patie$171,073
R21 · FY2014 · AG
Creation of a Risk-scoring Algorithm for Early Mortality Among Elderly ESRD Patie$169,283
R21 · FY2013 · AG
Erythropoiesis-stimulating agent use among chronic kidney disease patients$114,900
R21 · FY2012 · DK
Erythropoiesis-stimulating agent use among chronic kidney disease patients$114,900
R21 · FY2011 · DK
The Effect of Dialysis Chains on Mortality in Patients Receiving Hemodialysis$51,026
R03 · FY2010 · HS
Impact of Recent Payment Reform on Dialysis Modality Choice among ESRD Patients$50,716
R03 · FY2015 · HS
Do Safety Warnings Change Prescribing among the US Dialysis Population?$50,648
R03 · FY2012 · HS
Do Safety Warnings Change Prescribing among the US Dialysis Population?$49,092
R03 · FY2011 · HS
Impact of Recent Payment Reform on Dialysis Modality Choice among ESRD Patients$48,674
R03 · FY2014 · HS
Dialysis Chains and Access to Cadaveric Renal Transplantation Therapy$46,901
R03 · FY2011 · HS
Dialysis Chains and Access to Cadaveric Renal Transplantation Therapy$46,102
R03 · FY2012 · HS
The Effect of Dialysis Chains on Mortality in Patients Receiving Hemodialysis$44,240
R03 · FY2011 · HS